A Novel Intronic Mutation Reduces HAX1 Level and is Associated With Severe Congenital Neutropenia.


Journal

Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 04 09 2020
accepted: 14 12 2020
pubmed: 10 2 2021
medline: 17 2 2022
entrez: 9 2 2021
Statut: ppublish

Résumé

Severe congenital neutropenia (SCN) is a rare disease. Autosomal recessive forms of SCN are more frequent in countries where consanguineous marriages are common. In this report, we describe a 54-day-old female with neutropenia who presented with ecthyma gangrenosum. Clinical exome sequencing was used to identify the mutation. HAX1 messenger RNA and isoforms were examined by real-time quantitative and conventional polymerase chain reaction. Bone marrow aspiration was stained by hematoxylin and eosin. Granulocytes were tested for apoptosis upon H2O2 exposure. T-cell proliferation was tested by flow cytometry. Clinical exome sequencing revealed a novel homozygous acceptor splice site mutation in intron 3 of HAX1 (c.505-1G>C), which reduced both isoforms A and B of HAX1 messenger RNA. The Western blot studies showed a complete absence of HAX1 protein. The purified neutrophils from the patient showed increased apoptosis upon H2O2 exposure, whereas T-cell proliferative responses to various stimuli were intact. The patient was treated with combined antibiotics, filgrastim, and placed on antibiotics prophylaxis. To the best of our knowledge, our data provide the first experimental evidence for HAX1 deficiency because of a splice site mutation. Although 3 other splice site variants have been deposited in databases, functional studies were missing. This novel variant of HAX1 may explain the SCN and secondary infections in our patients.

Identifiants

pubmed: 33560082
doi: 10.1097/MPH.0000000000002071
pii: 00043426-202201000-00016
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
HAX1 protein, human 0
RNA Splice Sites 0
Hydrogen Peroxide BBX060AN9V

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e62-e67

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis. 2011;6:26.
Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49:609–614.
Zeidler C, Germeshausen M, Klein C, et al. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol. 2009;144:459–467.
Dale DC, Link DC. The many causes of severe congenital neutropenia. N Engl J Med. 2009;360:3–5.
Boztug K, Appaswamy G, Ashikov A, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med. 2009;360:32–43.
Klein C, Welte K. Genetic insights into congenital neutropenia. Clin Rev Allergy Immunol. 2010;38:68–74.
Boztug K, Klein C. Genetic etiologies of severe congenital neutropenia. Curr Opin Pediatr. 2011;23:21–26.
Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39:86–92.
Smith BN, Ancliff PJ, Pizzey A, et al. Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindreds. Br J Haematol. 2009;144:762–770.
Faiyaz-Ul-Haque M, Al-Jefri A, Al-Dayel F, et al. A novel HAX1 gene mutation in severe congenital neutropenia (SCN) associated with neurological manifestations. Eur J Pediatr. 2010;169:661–666.
Carlsson G, Melin M, Dahl N, et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr Int J Paediatr. 2007;96:813–819.
Germeshausen M, Grudzien M, Zeidler C, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood. 2008;111:4954–4957.
Ishikawa N, Okada S, Miki M, et al. Neurodevelopmental abnormalities associated with severe congenital neutropenia due to the R86X mutation in the HAX1 gene. J Med Genet. 2008;45:802–807.
Eken A, Cansever M, Somekh I, et al. Genetic deficiency and biochemical inhibition of ITK affect human Th17, Treg, and innate lymphoid cells. J Clin Immunol. 2019;39:391–400.
Boztug K, Ding XQ, Hartmann H, et al. HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. Am J Med Genet A. 2010;152a:3157–3163.
Rezaei N, Moazzami K, Aghamohammadi A, et al. Neutropenia and primary immunodeficiency diseases. Int Rev Immunol. 2009;28:335–336.
Lane E, Murray KF. Neonatal cholestasis. Pediatr Clin North Am. 2017;64:621–639.
Yilmaz Karapinar D, Patiroğlu T, Metin A, et al. Homozygous c.130–131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: report from the Turkish Severe Congenital Neutropenia Registry. Pediatr Blood Cancer. 2019;66:1–10.
Patiroglu T, Eke Gungor H, Triop A, et al. Severe congenital neutropenia in two siblings related to HAX1 mutation without neurodevelopmental disorders. Genet Couns. 2013;24:353–358.
Klein C. Congenital neutropenia. Stiehm’s Immune Deficiencies. 2014:605–618.

Auteurs

Serdar Goktas (S)

Departments of Pediatrics, Division of Pediatric Allergy and Immunology.

Zehra B Azizoglu (ZB)

Medical Biology.

Daniel Petersheim (D)

Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Merve Erdogan (M)

Pediatrics, Division of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University.

Hatice Eke Gungor (H)

Pediatric Allergy and Immunology Clinic, Kayseri City Hospital, Health Science University.

Atil Bisgin (A)

Adana Genetic Diseases Diagnosis and Treatment Center (AGENTEM).
Department of Medical Genetics, Faculty of Medicine, Cukurova University, Adana, Turkey.

Sevcan Tuğ Bozdoğan (S)

Adana Genetic Diseases Diagnosis and Treatment Center (AGENTEM).
Department of Medical Genetics, Faculty of Medicine, Cukurova University, Adana, Turkey.

Ahmet Eken (A)

Medical Biology.
Betül-Ziya Eren Genome and Stem Cell Center (GENKOK), Kayseri.

Ekrem Unal (E)

Pediatrics, Division of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University.
Betül-Ziya Eren Genome and Stem Cell Center (GENKOK), Kayseri.

Christoph Klein (C)

Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Turkan Patiroglu (T)

Departments of Pediatrics, Division of Pediatric Allergy and Immunology.
Pediatrics, Division of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH